ლეიშმანიოზი

Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.სრული ტექსტი  აბსტრაქტი

Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. აბსტრაქტი

Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. აბსტრაქტი

Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. აბსტრაქტი

Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].სრული ტექსტი

National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].სრული ტექსტი

1. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007 Sep;7(9):581-96. აბსტრაქტი

2. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov;5(11):873-82. აბსტრაქტი

3. Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol. 1999 May-Jun;17(3):279-89. აბსტრაქტი

4. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev. 2001 Oct;14(4):659-88.სრული ტექსტი  აბსტრაქტი

5. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008 Mar;8(3):191-9. აბსტრაქტი

6. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003 Feb;3(2):87-98. აბსტრაქტი

7. World Health Organization. The post kala-azar dermal leishmaniasis (PKDL) atlas: a manual for health workers. 2012 [internet publication].სრული ტექსტი

8. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.სრული ტექსტი  აბსტრაქტი

9. Cabello I, Caraballo A, Millan Y. Leishmaniasis in the genital area. Rev Inst Med Trop Sao Paulo. 2002 Mar-Apr;44(2):105-7.სრული ტექსტი  აბსტრაქტი

10. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000Res. 2017 May 26;6:750.სრული ტექსტი  აბსტრაქტი

11. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol. 2003 Oct;97 Suppl 1:107-14. აბსტრაქტი

12. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-76. აბსტრაქტი

13. Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop. 2008 Jan;105(1):1-9. აბსტრაქტი

14. Global Health Data Exchange. Global burden of disease study 2019 (GBD 2019) data resources [internet publication].სრული ტექსტი

15. World Health Organization. Fact sheet: leishmaniasis. Mar 2020 [internet publication].სრული ტექსტი

16. World Health Organization. Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014. Wkly Epidemiol Rec.2016:91:287-96.სრული ტექსტი

17. World Health Organization. Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic. Nov 2022 [internet publication].​სრული ტექსტი

18. Pan American Health Organization. Leishmaniasis: epidemiological report of the Americas, No. 10 (December 2021). Dec 2021 [internet publication].სრული ტექსტი

19. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008 Apr;21(2):334-59.სრული ტექსტი  აბსტრაქტი

20. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006 Jan;19(1):111-26.სრული ტექსტი  აბსტრაქტი

21. Wright NA, Davis LE, Aftergut KS, et al. Cutaneous leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008 Apr;58(4):650-2. აბსტრაქტი

22. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004 Feb;53(2):158-66.სრული ტექსტი  აბსტრაქტი

23. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM. 2004 Dec;97(12):781-8. აბსტრაქტი

24. Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004 Dec 1;39(11):1674-80.სრული ტექსტი  აბსტრაქტი

25. Pan American Health Organization. Leishmaniases. Epidemiological report of the Americas, December 2020. Dec 2020 [internet publication].სრული ტექსტი

26. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.სრული ტექსტი  აბსტრაქტი

27. World Health Organization. WHO responds to visceral leishmaniasis outbreak inKenya. Jun 2017 [internet publication].სრული ტექსტი

28. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006 Dec;22(12):552-7. აბსტრაქტი

29. Myles O, Wortmann GW, Cummings JF, et al. Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med. 2007 Sep 24;167(17):1899-901. აბსტრაქტი

30. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002 Aug 1;35(3):261-7.სრული ტექსტი  აბსტრაქტი

31. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and reserve components, U.S. Armed Forces, 2001-2016. MSMR. 2017 Feb;24(2):2-7. აბსტრაქტი

32. Mody RM, Lakhal-Naouar I, Sherwood JE, et al. Asymptomatic visceral Leishmania infantum infection in US soldiers deployed to Iraq. Clin Infect Dis. 2019 May 30;68(12):2036-44.სრული ტექსტი  აბსტრაქტი

33. Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg Infect Dis. 2006 Mar;12(3):440-6.სრული ტექსტი  აბსტრაქტი

34. Sereno D. Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens. New Microbes New Infect. 2019 Apr 4;30:100540.სრული ტექსტი  აბსტრაქტი

35. Leelayoova S, Siripattanapipong S, Manomat J, et al. Leishmaniasis in Thailand: a review of causative agents and situations. Am J Trop Med Hyg. 2017 Mar;96(3):534-42.სრული ტექსტი  აბსტრაქტი

36. Desbois N, Pratlong F, Quist D, et al. Leishmania (Leishmania) martiniquensis n. sp. (Kinetoplastida: Trypanosomatidae), description of the parasite responsible for cutaneous leishmaniasis in Martinique Island (French West Indies). Parasite. 2014;21:12.სრული ტექსტი  აბსტრაქტი

37. Depaquit J, Kaltenbach ML, Gay F. Visceral leishmaniasis in traveler to Guyana caused by Leishmania siamensis, London, UK. Emerg Infect Dis. 2018 Aug;24(8):1599-600.სრული ტექსტი  აბსტრაქტი

38. Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol. 2005;59:1-75. აბსტრაქტი

39. Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun. 2002 Dec;70(12):6919-25.სრული ტექსტი  აბსტრაქტი

40. Weirather JL, Duggal P, Nascimento EL, et al. Comprehensive candidate gene analysis for symptomatic or asymptomatic outcomes of Leishmania infantum infection in Brazil. Ann Hum Genet. 2017 Jan;81(1):41-8.სრული ტექსტი  აბსტრაქტი

41. Rogers ME, Ilg T, Nikolaev AV, et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature. 2004 Jul 22;430(6998):463-7. აბსტრაქტი

42. Vannier-Santos MA, Martiny A, de Souza W. Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des. 2002;8(4):297-318. აბსტრაქტი

43. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000 Nov;2(14):1765-73. აბსტრაქტი

44. Belkaid Y, Valenzuela JG, Kamhawi S, et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly? Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6704-9.სრული ტექსტი  აბსტრაქტი

45. Warburg A, Saraiva E, Lanzaro GC, et al. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Philos Trans R Soc Lond B Biol Sci. 1994 Jul 29;345(1312):223-30. აბსტრაქტი

46. Basu MK, Ray M. Macrophage and Leishmania: an unacceptable coexistence. Crit Rev Microbiol. 2005;31(3):145-54. აბსტრაქტი

47. Kariyawasam KKGDUL, Selvapandiyan A, Siriwardana HVYD, et al. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies. Parasitology. 2018 Apr;145(4):443-52.სრული ტექსტი  აბსტრაქტი

48. Zhang WW, Ramasamy G, McCall LI, et al. Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog. 2014 Jul;10(7):e1004244.სრული ტექსტი  აბსტრაქტი

49. Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis. 1987 Dec;156(6):1030-3. აბსტრაქტი

50. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 1999 Aug;13(8):459-65. აბსტრაქტი

51. Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005 May;11(5):655-62.სრული ტექსტი  აბსტრაქტი

52. Brooker S, Mohammed N, Adil K, et al. Leishmaniasis in refugee and local Pakistani populations. Emerg Infect Dis. 2004 Sep;10(9):1681-4.სრული ტექსტი  აბსტრაქტი

53. Kolaczinski JH, Reithinger R, Worku DT, et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008 Apr;37(2):344-52. აბსტრაქტი

54. Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):184-8.სრული ტექსტი  აბსტრაქტი

55. Pennisi MG, Cardoso L, Baneth G, et al. LeishVet update and recommendations on feline leishmaniosis. Parasit Vectors. 2015 Jun 4;8:302.სრული ტექსტი  აბსტრაქტი

56. Asfaram S, Fakhar M, Teshnizi SH. Is the cat an important reservoir host for visceral leishmaniasis? A systematic review with meta-analysis. J Venom Anim Toxins Incl Trop Dis. 2019 Jun 10;25:e20190012.სრული ტექსტი  აბსტრაქტი

57. Public Health England. HAIRS risk assessment: canine leishmaniosis. Jan 2022 [internet publication].სრული ტექსტი

58. World Veterinary Association. WVA policies: WVA position statement on Leishmaniosis. Apr 2021 [internet publication].სრული ტექსტი

59. Kopterides P, Mourtzoukou EG, Skopelitis E, et al. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1181-9. აბსტრაქტი

60. Català A, Roé E, Dalmau J, et al. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015;230(3):204-7.სრული ტექსტი  აბსტრაქტი

61. Arens K, Filippis C, Kleinfelder H, et al. Anti-tumor necrosis factor α therapeutics differentially affect Leishmania infection of human macrophages. Front Immunol. 2018 Jul 31;9:1772.სრული ტექსტი  აბსტრაქტი

62. World Health Organization. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. June 2022 [internet publication].სრული ტექსტი

63. Stockdale L, Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis. 2013 Jun 20;7(6):e2278.სრული ტექსტი  აბსტრაქტი

64. Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011 Apr;11(4):322-5. აბსტრაქტი

65. Romero GA, Boelaert M. Control of visceral leishmaniasis in Latin America: a systematic review. PLoS Negl Trop Dis. 2010 Jan 19;4(1):e584.სრული ტექსტი  აბსტრაქტი

66. González U, Pinart M, Sinclair D, et al, Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev. 2015 Aug 5;2015(8):CD008736.სრული ტექსტი  აბსტრაქტი

67. Picado A, Singh SP, Rijal S, et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ. 2010 Dec 29;341:c6760.სრული ტექსტი  აბსტრაქტი

68. Chowdhury R, Dotson E, Blackstock AJ, et al. Comparison of insecticide-treated nets and indoor residual spraying to control the vector of visceral leishmaniasis in Mymensingh District, Bangladesh. Am J Trop Med Hyg. 2011 May;84(5):662-7. აბსტრაქტი

69. Costa CH. How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):232-42.სრული ტექსტი  აბსტრაქტი

70. Sousa-Paula LC, Silva LGD, Sales KGDS, et al. Failure of the dog culling strategy in controlling human visceral leishmaniasis in Brazil: a screening coverage issue? PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0007553.სრული ტექსტი  აბსტრაქტი

71. Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis. 1991 Sep-Oct;13(5):1009-17. აბსტრაქტი

72. Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis. 2017 May 12;11(5):e0005527.სრული ტექსტი  აბსტრაქტი

73. ClinicalTrials.gov. A study to assess the safety, efficacy and immunogenicity of leishmania vaccine ChAd63-KH in PKDL. Apr 2020 [internet publication].სრული ტექსტი

74. ClinicalTrials.gov. A study of a new leishmania vaccine candidate ChAd63-KH (Leish2a). Jan 2020 [internet publication].სრული ტექსტი

75. Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021 Jul 7;29(7):2366-77.სრული ტექსტი  აბსტრაქტი

76. Boelaert M, Bhattacharya S, Chappuis F, et al. Evaluation of rapid diagnostic tests: visceral leishmaniasis. Nat Rev Microbiol. 2007;5(suppl):S30-9.

77. Escobar MA, Martinez F, Scott Smith D, et al. American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop Doct. 1992;22 Suppl 1:69-78;63-4. აბსტრაქტი

78. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007 Jan;45(1):21-5.სრული ტექსტი  აბსტრაქტი

79. Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. აბსტრაქტი

80. Sevilha-Santos L, Dos Santos Júnior ACM, Medeiros-Silva V, et al. Accuracy of qPCR for quantifying Leishmania kDNA in different skin layers of patients with American tegumentary leishmaniasis. Clin Microbiol Infect. 2019 Feb;25(2):242-7.სრული ტექსტი  აბსტრაქტი

81. Cota GF, de Sousa MR, Demarqui FN, et al. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012;6(5):e1665.სრული ტექსტი  აბსტრაქტი

82. Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol. 2006 Jul;44(7):2343-7.სრული ტექსტი  აბსტრაქტი

83. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):673-5. აბსტრაქტი

84. De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg. 2006 Oct;75(4):739-43.სრული ტექსტი  აბსტრაქტი

85. Boelaert M, Rijal S, Regmi S, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg. 2004 Jan;70(1):72-7.სრული ტექსტი  აბსტრაქტი

86. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis. 2000 Oct;31(4):1093-5.სრული ტექსტი  აბსტრაქტი

87. Weigle KA, de Dávalos M, Heredia P, et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg. 1987 May;36(3):489-96. აბსტრაქტი

88. Kager PA, Rees PH. Splenic aspiration. Review of the literature. Trop Geogr Med. 1983 Jun;35(2):111-24. აბსტრაქტი

89. Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):505-7. აბსტრაქტი

90. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005 Jun;72(6):811-4. აბსტრაქტი

91. Schuster FL, Sullivan JJ. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev. 2002 Jul;15(3):374-89.სრული ტექსტი  აბსტრაქტი

92. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002 Sep;9(5):951-8.სრული ტექსტი  აბსტრაქტი

93. Maurya R, Singh RK, Kumar B, et al. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. J Clin Microbiol. 2005 Jul;43(7):3038-41.სრული ტექსტი  აბსტრაქტი

94. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ. 2006 Oct 7;333(7571):723.სრული ტექსტი  აბსტრაქტი

95. Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev. 2014 Jun 20;2014(6):CD009135.სრული ტექსტი  აბსტრაქტი

96. Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):32-40. აბსტრაქტი

97. de Assis TS, Braga AS, Pedras MJ, et al. Multi-centric prospective evaluation of rk39 rapid test and direct agglutination test for the diagnosis of visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2011 Feb;105(2):81-5. აბსტრაქტი

98. Harith AE, Kolk AH, Kager PA, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg. 1987;81(4):603-6. აბსტრაქტი

99. Iqbal J, Hira PR, Saroj G, et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol. 2002 Feb;40(2):475-9.სრული ტექსტი  აბსტრაქტი

100. Marty P, Lelièvre A, Quaranta JF, et al. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):690-1. აბსტრაქტი

101. Singh RK. Hyperreactive malarial splenomegaly in expatriates. Travel Med Infect Dis. 2007 Jan;5(1):24-9. აბსტრაქტი

102. World Health Organization. WHO Guidelines for malaria. Jun 2022 [internet publication].სრული ტექსტი

103. Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006 Sep 23;368(9541):1106-18. აბსტრაქტი

104. Schaefer KU, Kurtzhals JA, Gachihi GS, et al. A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):471-5. აბსტრაქტი

105. Davies CR, Llanos-Cuentas EA, Pyke SD, et al. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect. 1995 Apr;114(2):297-318.სრული ტექსტი  აბსტრაქტი

106. Cardo LJ. Leishmania: risk to the blood supply. Transfusion. 2006 Sep;46(9):1641-5. აბსტრაქტი

107. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. აბსტრაქტი

108. Martínez-Valencia AJ, Daza-Rivera CF, Rosales-Chilama M, et al. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005713.სრული ტექსტი  აბსტრაქტი

109. Dereure J, Duong Thanh H, Lavabre-Bertrand T, et al. Visceral leishmaniasis: persistence of parasites in lymph nodes after clinical cure. J Infect. 2003 Jul;47(1):77-81. აბსტრაქტი

110. Berman JD. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999 Jan;28(1):49-51.სრული ტექსტი  აბსტრაქტი

111. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 998;76(1):25-32.სრული ტექსტი  აბსტრაქტი

112. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006 Oct 1;43(7):917-24.სრული ტექსტი  აბსტრაქტი

113. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005 Dec;5(12):763-74. აბსტრაქტი

114. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004 Feb 1;38(3):377-83.სრული ტექსტი  აბსტრაქტი

115. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000 Feb;13(4):243-8. აბსტრაქტი

116. Carnielli JBT, Crouch K, Forrester S, et al. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. EBioMedicine. 2018 Oct;36:83-91.სრული ტექსტი  აბსტრაქტი

117. Tiwary P, Kumar D, Sundar S. Identification and functional validation of a biomarker for the diagnosis of miltefosine relapse during visceral leishmaniasis. Am J Trop Med Hyg. 2018 Feb;98(2):492-6.სრული ტექსტი  აბსტრაქტი

118. Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother. 2006 Oct;58(4):811-5.სრული ტექსტი  აბსტრაქტი

119. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother. 2005 Feb;55(2):229-33.სრული ტექსტი  აბსტრაქტი

120. Pekelharing JE, Gatluak F, Harrison T, et al. Outcomes of visceral leishmaniasis in pregnancy: a retrospective cohort study from South Sudan. PLoS Negl Trop Dis. 2020 Jan;14(1):e0007992.სრული ტექსტი  აბსტრაქტი

121. Sundar S, Chakravarty J. Antimony toxicity. Int J Environ Res Public Health. 2010 Dec;7(12):4267-77.სრული ტექსტი  აბსტრაქტი

122. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 2001 Nov;6(11):849-54.სრული ტექსტი  აბსტრაქტი

123. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8(4):319-42. აბსტრაქტი

124. Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007 Aug;77(2):266-74. აბსტრაქტი

125. Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011 May;118(2):87-96. აბსტრაქტი

126. Heras-Mosteiro J, Monge-Maillo B, Pinart M, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067.სრული ტექსტი  აბსტრაქტი

127. Pinart M, Rueda JR, Romero GA, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD004834.სრული ტექსტი  აბსტრაქტი

128. Morizot G, Kendjo E, Mouri O, et al. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis. 2013 Aug;57(3):370-80.სრული ტექსტი  აბსტრაქტი

129. López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, et al. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016 Jul 26;16:360.სრული ტექსტი  აბსტრაქტი

130. Cardona-Arias JA, Vélez ID, López-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. 2015 May 26;10(5):e0122569.სრული ტექსტი  აბსტრაქტი

131. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. აბსტრაქტი

132. Sosa N, Pascale JM, Jiménez AI, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019 May 2;13(5):e0007253.სრული ტექსტი  აბსტრაქტი

133. Soto J, Soto P, Ajata A, et al. Topical 15% paromomycin-aquaphilic for Bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clin Infect Dis. 2019 Feb 15;68(5):844-9.სრული ტექსტი  აბსტრაქტი

134. Kim DH, Chung HJ, Bleys J, et al. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3(2):e381.სრული ტექსტი  აბსტრაქტი

135. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One. 2017 Sep 19;12(9):e0184777.სრული ტექსტი  აბსტრაქტი

136. Soto J, Paz D, Rivero D, et al. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2016 Apr;94(4):852-6.სრული ტექსტი  აბსტრაქტი

137. Galvão EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS One. 2017 Oct 9;12(10):e0186117.სრული ტექსტი  აბსტრაქტი

138. Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. აბსტრაქტი

139. Roussel M, Nacher M, Frémont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006 Jun;100(4):307-14. აბსტრაქტი

140. Lai A Fat EJ, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol. 2002 Nov;41(11):796-800. აბსტრაქტი

141. Christen JR, Bourreau E, Demar M, et al. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Med Infect Dis. 2018 Jul - Aug;24:31-6. აბსტრაქტი

142. Soto J, Soto P, Ajata A, et al. Miltefosine combined with intralesional pentamidine for Leishmania braziliensis cutaneous leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018 Nov;99(5):1153-5.სრული ტექსტი  აბსტრაქტი

143. Dorlo TP, Kager PA. Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis. 2008 May 28;2(5):e225.სრული ტექსტი  აბსტრაქტი

144. Machado PR, Rosa ME, Guimarães LH, et al. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clin Infect Dis. 2015 Sep 15;61(6):945-9.სრული ტექსტი  აბსტრაქტი

145. Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].სრული ტექსტი

146. Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007 Aug;46(8):848-52. აბსტრაქტი

147. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis. 2007 Aug 15;45(4):478-82.სრული ტექსტი  აბსტრაქტი

148. Avila-García M, Mancilla-Ramírez J, Segura-Cervantes E, et al. Transplacental transmission of cutaneous Leishmania mexicana strain in BALB/c mice. Am J Trop Med Hyg. 2013 Aug;89(2):354-8.სრული ტექსტი  აბსტრაქტი

149. Pan American Health Organization. Manual of procedures for leishmaniases surveillance and control in the Americas. Dec 2019 [internet publication].სრული ტექსტი

150. Cunha MA, Leão AC, de Cassia Soler R, et al. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the New World: a retrospective study. Am J Trop Med Hyg. 2015 Dec;93(6):1214-8.სრული ტექსტი  აბსტრაქტი

151. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007 Feb 1;44(3):350-6.სრული ტექსტი  აბსტრაქტი

152. Osman OF, Oskam L, Zijlstra EE, et al. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment. Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):397-400. აბსტრაქტი

153. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11;362(6):504-12.სრული ტექსტი  აბსტრაქტი

154. Lucero E, Collin SM, Gomes S, et al. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis. 2015 Apr 2;9(4):e0003699.სრული ტექსტი  აბსტრაქტი

155. Goswami RP, Goswami RP, Das S, et al. Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome™). Am J Trop Med Hyg. 2016 Jan;94(1):93-8.სრული ტექსტი  აბსტრაქტი

156. Pandey K, Pal B, Siddiqui NA, et al. Efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India. Am J Trop Med Hyg. 2017 Nov;97(5):1498-502.სრული ტექსტი  აბსტრაქტი

157. Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635.სრული ტექსტი  აბსტრაქტი

158. Goyal V, Mahajan R, Pandey K, et al. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl Trop Dis. 2018 Oct 22;12(10):e0006830.სრული ტექსტი  აბსტრაქტი

159. Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis. 2015 Oct;28(5):426-37. აბსტრაქტი

160. Gebreyohannes EA, Bhagvathula AS, Abegaz TM, et al. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018 Oct 19;7(1):108.სრული ტექსტი  აბსტრაქტი

161. Romero GAS, Costa DL, Costa CHN, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005706.სრული ტექსტი  აბსტრაქტი

162. Assis TSM, Rabello A, Cota G, et al. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180272.სრული ტექსტი  აბსტრაქტი

163. Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance programme. Clin Drug Investig. 2017 Mar;37(3):259-72.სრული ტექსტი  აბსტრაქტი

164. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011 Feb 5;377(9764):477-86. აბსტრაქტი

165. Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21;356(25):2571-81.სრული ტექსტი  აბსტრაქტი

166. Jamil KM, Haque R, Rahman R, et al. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118.სრული ტექსტი  აბსტრაქტი

167. Akuffo H, Costa C, van Griensven J, et al. New insights into leishmaniasis in the immunosuppressed. PLoS Negl Trop Dis. 2018 May 10;12(5):e0006375.სრული ტექსტი  აბსტრაქტი

168. Gajurel K, Dhakal R, Deresinski S. Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients. Clin Transplant. 2017 Jan;31(1). აბსტრაქტი

169. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].სრული ტექსტი

170. World Health Organization. WHO technical report series 949: control of the leishmaniases - report of a meeting of the WHO Expert Committee on the control of leishmaniases. 2010 [internet publication].სრული ტექსტი

171. Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988.სრული ტექსტი  აბსტრაქტი

172. Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-Miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-Arm, phase 3 trial. Clin Infect Dis. 2022 Oct 12;75(8):1423-32.სრული ტექსტი  აბსტრაქტი

173. Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013 May 2;7(5):e2195.სრული ტექსტი  აბსტრაქტი

174. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS. 1999 Jun 18;13(9):1063-9. აბსტრაქტი

175. Delgado J, Macías J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999 Nov;61(5):766-9. აბსტრაქტი

176. Diro E, Edwards T, Ritmeijer K, et al. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. PLoS Negl Trop Dis. 2019 Feb 21;13(2):e0007132.სრული ტექსტი  აბსტრაქტი

177. Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018 Jan 18;66(3):444-51.სრული ტექსტი  აბსტრაქტი

178. Clemente W, Vidal E, Girão E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015 Jan;21(1):89-95.სრული ტექსტი  აბსტრაქტი

179. Pijpers J, den Boer ML, Essink DR, et al. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - a review and meta-analysis. PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007173.სრული ტექსტი  აბსტრაქტი

180. World Health Organization. Statement on miltefosine - potential ocular disorders in patients treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL). Feb 2022 [internet publication].სრული ტექსტი

181. Basher A, Maruf S, Nath P, et al. Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh – a series of four cases. Am J Trop Med Hyg. 2017 Oct;97(4):1111-5.სრული ტექსტი  აბსტრაქტი

182. Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005 Sep;99(6):563-9. აბსტრაქტი

183. Moulik S, Chaudhuri SJ, Sardar B, et al. Monitoring of parasite kinetics in Indian post-kala-azar dermal leishmaniasis. Clin Infect Dis. 2018 Jan 18;66(3):404-10.სრული ტექსტი  აბსტრაქტი

184. Ramesh V, Dixit KK, Sharma N, et al. Assessing the efficacy and safety of liposomal amphotericin B and miltefosine in combination for treatment of post kala-azar dermal leishmaniasis. J Infect Dis. 2020 Feb 3;221(4):608-17.სრული ტექსტი  აბსტრაქტი

185. World Health Organization. WHO technical report series 949: control of the leishmaniases – report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. 2010 [internet publication].სრული ტექსტი

186. World Health Organization. South Sudan intensifies measures against visceral leishmaniasis to improve health and social well-being of affected populations. Nov 2018 [internet publication].სრული ტექსტი

187. Drugs for Neglected Diseases initiative. Fexinidazole/miltefosine combination (VL). Aug 2016 [internet publication].სრული ტექსტი

188. Drugs for Neglected Diseases Initiative. DNDI-0690. Aug 2019 [internet publication].სრული ტექსტი

189. ClinicalTrials.gov. Single oral dose escalation study of DNDI-0690 in healthy male subjects. Apr 2019 [internet publication].სრული ტექსტი

190. Drugs for Neglected Diseases initiative. R&D portfolio update February 2019: DNDi Leishmaniasis programme. Feb 2019 [internet publication].სრული ტექსტი

191. ClinicalTrials.gov. Safety, tolerability and pharmacokinetics (PKs) investigation of GSK3186899 in healthy subjects. Apr 2020 [internet publication].სრული ტექსტი

192. Alves F, Bilbe G, Blesson S, et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018 Oct;31(4):.სრული ტექსტი  აბსტრაქტი

193. Drugs for Neglected Diseases initiatives. Annual report 2020: medicines for the people. 2020 [internet publication].სრული ტექსტი

194. Hossain MS, Kumar A, Hossain AFMA, et al. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infect Dis Poverty. 2018 Aug 13;7(1):80.სრული ტექსტი  აბსტრაქტი

195. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006 Aug 1;43(3):357-64.სრული ტექსტი  აბსტრაქტი

196. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004 Mar 1;38(5):612-9.სრული ტექსტი  აბსტრაქტი

197. Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol. 2008 Jan;102(1):11-9.სრული ტექსტი  აბსტრაქტი

198. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011 Jun;5(6):e1153.სრული ტექსტი  აბსტრაქტი